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Abstract
Background: The study of human B cell response to dengue virus (DENV) infection is critical to understand
serotype-specific protection and the cross-reactive sub-neutralizing response. Whereas the first is beneficial and thus
represents the ultimate goal of vaccination, the latter has been implicated in the development of severe disease,
which occurs in a small, albeit significant, fraction of secondary DENV infections. Both primary and secondary
infections are associated with the production of poly-reactive and cross-reactive IgG antibodies.
Methods: To gain insight into the effect of DENV infection on the B cell repertoire, we used VH region
high-throughput cDNA sequencing of the peripheral blood IgG B cell compartment of 19 individuals during the
acute phase of infection. For 11 individuals, a second sample obtained 6 months later was analyzed for comparison.
Probabilities of sequencing antibody secreting cells or memory B cells were estimated using second-order Monte
Carlo simulation.
Results: We found that in acute disease there is an increase in IgG B cell diversity and changes in the relative use
of segments IGHV1-2, IGHV1-18, and IGHV1-69. Somewhat unexpectedly, an overall low proportion of somatic
hypermutated antibody genes was observed during the acute phase plasmablasts, particularly in secondary
infections and those cases with more severe disease.
Conclusions: Our data are consistent with an innate-like antiviral recognition system mediated by B cells using
defined germ-line coded B cell receptors, which could provide a rapid germinal center-independent antibody
response during the early phase of infection. A model describing concurrent T-dependent and T-independent B cell
responses in the context of DENV infection is proposed, which incorporates the selection of B cells using
hypomutated IGHV segments and their potential role in poly/cross-reactivity. Its formal demonstration could lead to
a definition of its potential implication in antibody-dependent enhancement, and may contribute to rational
vaccine development efforts.
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Background
Dengue, the most prevalent mosquito borne-viral disease
in humans, is caused by four closely related serotypes of
dengue virus (DENV) of the Flaviviridae family. The in-
fection can be asymptomatic, produce a mild self-limited
febrile disease lasting up to 10 days, or result in a severe
disease with hemostatic and hemodynamic dysfunction
[1, 2]. According to recent estimates, 390 million dengue
infections occur each year, of which only 96 million
reach the public health surveillance system [3].
DENV primarily infects dendritic cells and monocytes
[4–6]. During the early stages of infection, a rapid, strong
innate immune response is elicited, resulting in a systemic
inflammatory immune response that explains the majority
of symptoms of uncomplicated illness. Shortly after, an
adaptive immune response manifests as the production of
low-affinity IgM anti-DENV antibodies, and, later, high-
affinity anti-DENV IgG-neutralizing antibodies that confer
long-term protection to the infecting serotype (homotypic
protection). However, primary infections are also associ-
ated with the production of low-affinity, non-neutralizing
or sub-neutralizing cross-reactive antibodies against mul-
tiple DENV-serotypes that only confer partial short-term
protection [7].
An almost paradigmatic feature of dengue infection is
the epidemiological observation that severe illness is as-
sociated with a previous infection with a different DENV
serotype [8]. Non-neutralizing cross-reactive antibodies
induced during primary infections have been implicated
in potentiating viral replication, systemic immunopathol-
ogy, and severe disease by FcγR-mediated antibody-
dependent enhancement (ADE), offering a plausible ex-
planation of the increased disease severity after multiple
reinfections [9].
Antibody production is the result of B cell clonal se-
lection, expansion, and differentiation into antibody-
secreting plasma cells. In the case of protein antigens,
antigen-specific B cells are clonally selected and form
germinal centers (GC) depending on T cell help. Within
the GC, selected B cells undergo somatic hypermutation
(SHM) and class switch recombination (CSR) [10, 11],
which are two mechanistically coupled processes result-
ing in high affinity IgG-switched memory B (mB) cells
and antibody-secreting plasma cells [12]. However, it has
become increasingly clear that B cell memory is hetero-
geneous in terms of their origin and function [13]. In
the context of DENV infection, the generation of long-
lived anti-DENV IgG+ memory cells selected by a pri-
mary infection has been implicated in the predominance
of neutralizing antibodies against the primary infecting
serotype over neutralizing antibodies specific for a differ-
ent serotype causing a secondary infection [14]. Presum-
ably, this so-called original antigenic sin could also favor
ADE by outcompeting secondary serotype anti-DENV
high-affinity B cell clones. Consistently, poly-reactive
and serotype cross-reactive IgGs are present in high ti-
ters in early primary and secondary DENV infections
[15–19]. Thus, understanding B cell responses to DENV
infection as well as antibody-mediated immune protec-
tion and enhancement requires the integrative analysis
of the clonal selection process within the actual concep-
tual framework of pathway heterogeneity of effector B
cell differentiation [13].
Given the central role of antibodies and their affinity
in the protection against DENV and their implication in
severe disease, we hypothesized that the B cell clonal se-
lection process and diversification may be different be-
tween primary and secondary dengue infections, and
between DENV infections without clinical warning signs
(DWS−) and dengue infections with clinical warning
signs (DWS+). To identify these differences, we used
high-throughput sequencing (HTS) of peripheral blood
IgG antibody repertoires derived from cDNA (reviewed
in [20, 21]) to compare clonal diversity, IGHV usage,
and SHM rates between patients with acute DWS− and
DWS+ and their corresponding post-convalescent blood
samples (6 months after).
We found differential changes in IGHV1-2, IGHV1-18,
and IGHV1-69 clonal usage frequency and transcription.
Paradoxically, we observed overall lower SHM rates dur-
ing acute illness, particularly in DWS+ and in lymphocytes
using IGHV1-2, suggesting their implication in cross-
reactive low-affinity IgG antibodies. Our results also sug-
gest that in humans infected with DENV, in addition to a
classical GC pathway, an alternative GC-independent ef-
fector B cell differentiation pathway may take place, in
which CSR to IgG is decoupled from SHM.
Methods
Ethics statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki. The study was
approved by the Research, Ethics and Biosafety Committees
of the Instituto Nacional de Salud Pública (CI:1023/1100),
Universidad Veracruzana, Integral Molecular and Instituto
de Diagnóstico y Referencia Epidemiológicos (InDRE).
Written informed consent was obtained from all
participants.
Patients, donors, and samples
During dengue season 2010 and 2011, 19 adult patients
with clinical and laboratory confirmed DENV infection
living in Veracruz, a DENV endemic zone in Mexico
[22], were enrolled after providing written informed
consent. Patients were classified as DWS+ if they re-
quired hospitalization, had hematocrit > 40, a platelet
count < 100 × 103, and at least one of the following
signs: abdominal pain or tenderness, persistent vomiting,
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clinical fluid accumulation, mucosal bleeding, lethargy,
restlessness, or liver enlargement (>2 cm). Patients do-
nated two peripheral blood samples to provide total RNA
and serum: one during the febrile stage (acute sample)
and the other 6 months after recovery (post-convalescent
sample), coinciding with the low transmission season to
minimize the possibility of asymptomatic reinfection. For
some data analyses, an additional control group of 10
healthy volunteers enrolled in an influenza vaccination
study [23], was included. Peripheral blood was collected to
obtain serum and total RNA. For RNA isolation, 2.5 ml of
peripheral blood in PaxGene RNA tubes (QIAGEN
GmbH, Hilden, Germany) was used according to manu-
facturer’s instructions and stored at −70 °C until use.
DENV serological diagnosis of primary and secondary
cases
All sera were tested with reference anti-NS1 enzyme-
linked immunosorbent assay (ELISA) with the Platelia
Dengue NS1 Ag Test (Bio-Rad, Marnes-la-Coquette,
France) and Dengue IgM (Panbio®, Sinnamon Park,
QLD, Australia). To discriminate between primary and
secondary infections, we used the IgG Capture ELISA
(Panbio®). Primary cases were defined as a positive
reverse-transcriptase polymerase chain reaction (RT-
PCR), NS1, and/or anti-IgM ELISA and negative anti-
IgG ELISA. Secondary cases were defined as positive
anti-IgG ELISA and NS1/or RT-PCR, regardless of the
results of the anti-IgM ELISA.
Dengue virus genotyping
Viral RNA was isolated from the sera during the acute
febrile phase (QIAamp Viral RNA mini kit, Qiagen)
and used to determinate DENV serotype by quantita-
tive RT-PCR according to the protocol of InDRE,
Mexico [24], and the Official Mexican Norm: NOM-
032-SSA-2002 [25].
DENV reporter virus particles neutralization assay
DENV reporter virus particles (RVPs) for the four sero-
types [26] were pre-incubated with an equal volume of
all serially diluted acute sera (1:10 to 1:10,240; all
dilutions were pre-incubated with RVPs) in complete
Dulbecco’s Modified Eagle Medium for 1 h at room
temperature with slow agitation. Following incubation,
BHK DC-SIGN cells were added to each well at a dens-
ity of 30,000 cells per well, followed by incubation at
37 °C in 5 % CO2 for 72 h. Cells were subsequently lysed
and analyzed for luciferase luminescent reporter expres-
sion. The percent infection for each concentration of
serum was calculated using Prism software 5.0 and raw
data expressed as percent infection versus log10 of the
reciprocal serum dilution. A sigmoidal dose–response
curve with a variable slope was applied to determine the
titer of antibody that achieved a 50 % reduction in infec-
tion (50 % neutralization titer, NT50). Maximum infection
was determined using a no serum control. An NT50 ≥ 1:50
was defined as a positive neutralization test.
VH libraries and high throughput cDNA sequencing
The RNA concentration and integrity was analyzed
through capillary electrophoresis in an Agilent 2100
BioAnalyzer, with the RNA 6000 Pico kit. cDNA was
generated for the VH region of IgG through 5′ rapid
amplification of cDNA ends (RACE)-PCR, using a
protocol modified from the SMART RACE cDNA Amp-
lification Kit (Clontech Laboratories, Inc.). The forward
primer (FpAmpTA) was a modification from the UPM
primer to which we added to the 5′ end an A adapter
from the platform GS FLX Titanium 454-Roche. The re-
verse primer TBIgGHu [5′-(454adaptorB)CTA TGC
GCC TTG CCA GCC CGC (454key) TCAG(IGHG)
ACC GAT GGG CCC TTG GTG-3′] primes in Exon I
of the IGHG genes and has the B adapter for the 454-
Roche sequencing [27]. We analyzed the 500–600 bp 5′
RACE-PCR products with 1.5 % agarose gel electrophor-
esis and purified them with a MiniElute PCR purification
kit (Qiagen). Their concentration and integrity was ana-
lyzed through capillary electrophoresis in a 2100 BioA-
nalyzer using the High Sensitivity DNA 2100 LabChip
(Agilent Technologies).
We used 100 ng of each library for the emulsion PCR
(GS emPCR Kit, 454-Roche). HTS was performed using
Genome Sequencer FLX Titanium System 454-Roche
with the GS LR70 Sequencing Kit according to the man-
ufacturer’s instructions. This platform generates an aver-
age read length of 450–500 bp. We performed the
sequencing with the B adapter (3′→ 5′) so that the
complementarity determining region heavy 3 (CDRH3)
region was proximal and the 5′ UTR was the sequencing
primer, allowing higher sequencing quality in the major-
ity of the IGHV coding region. Raw sequencing files are
available in NCBI-SRA: BioProject ID: PRJNA302665;
accession number: SAMN04277236-65.
Bioinformatics analysis
Estimation of probabilities of sampling either IgG+
antibody-secreting cells or memory B cells
To overcome the limitation of working with unsorted
IgG+ B cell subpopulations [antibody-secreting cells
(ASC) or mB], we designed a computational protocol
consisting of a second-order Monte Carlo simulation to
estimate the probability of picking a progressive number
of clonally related sequencing reads belonging to either
population for each cell sampled, during the acute dis-
ease and post-convalescence [28]. The model accounts
for individual variation over a gradient of relative pro-
portions of ASC and mB cells, as well as cellular
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variation in the relative Ig transcription levels in both
subpopulations. Briefly, the protocol calculates the prob-
ability of sampling Ig transcripts from either subpopula-
tion by random sampling distributions corresponding to
the relative amount of either subpopulation in a blood
sample, as well as the relative amount of Ig transcripts
per cell. The process is calculated in 500 individuals, for
a given mB cell to ASC ratio that begins with 1 % of
ASCs in post-convalescent individuals and ends with
1 % of mB cells (Additional file 1). In the simulation, an
average of 1000 IgG+ B cells having a normal distribu-
tion and 5 % variance were randomly sampled. The Ig
expression in mB cells has a normal distribution with a
mean of 100 arbitrary units (au) and 5 % variance, and
the Ig expression in ASCs follows a gamma distribution
with central value of 1200 au (12-fold increase relative
to an mB cell), a minimal value of 300, and a maximal
value of 10,000 au [29] (Additional file 1).
Pre-processing and repertoire reconstruction
We have developed a software (pipeline) named Immu-
nediveRsity for the analysis of the repertoire sequencing
(Rep-Seq) data [30]. ImmunediveRsity is written in R lan-
guage [31] and automates Ig sequencing analysis from
pre-processing, error correction and quality filtering,
V(D)J segment assignment, CDRH3-based sequence
clustering for heavy chain clonotypes, and their further
clustering into heavy chain lineages as a result of clono-
type diversification by SHM (referred hereafter as clono-
types and lineages, respectively. Additional file 2). Raw
sequences with an average ≥Q28 value and reads ≥250 bp
passed the quality filter. In order to exclude non-VH se-
quences, ImmunediveRsity assigns IGHV and IGHJ seg-
ment use to each read using IgBLAST [32]. A clonotype is
composed by reads that share the same V and J segment
and their CDRH3 has the same length and is 97 % iden-
tical [30]. To discard a possible effect of a CDRH3 clus-
tering threshold on SHM, repertoire data are also
reconstructed at a 92 % identity threshold. Reads be-
longing to a clonotype are further clustered along the
whole coding region, excluding the signal peptide, so
that the lineage is the consensus of reads sharing 99.5 %
identity (Additional file 2). For the analysis of IGHV
usage, collapsing sequences according to a common
clonal origin and to a particular lineage allows the fre-
quency to be expressed according to total clonotypes or
lineages, regardless of Ig transcription levels. Thus, a
given clonotype composed of 80 % of the sequencing
reads has an equal clonotype frequency to that of a clo-
notype composed of 0.1 % of the sequenced reads. The
same applies for lineages. For ImmunediveRsity, a
lineage is an approximation of a single B cell, although
it is possible to underestimate the true B cell numbers
(for example, when two B cells from the same clonotype
are identical or the proportion of SHM is below the
clustering threshold of 99.5 % identity). ImmunediveRsity
output files for each sequenced library can be found at
http://201.131.57.23:8080/dengue-project-2015/.
Estimation of sample B cell diversity
ImmunediveRsity calculates clonotype and lineage en-
tropy values (Shannon Index) [33, 34] and performs a
rarefaction analysis [35] as indirect measures of lymphocyte
diversity. The number of reads per clonotype and lineage
obtained for each sample (acute or post-convalescent
phase) was used to calculate the Shannon Index. Rarefac-
tion curves were calculated with the number of clonotypes
in growing subsamples of 1000 reads.
IGHV segment overrepresentation analysis
We used three approaches to identify overrepresented
IGHV segments during acute DENV infection. The first
approach aimed to reflect IGHV use based on the esti-
mation of IGHV segment relative transcription levels, re-
gardless of clonotype and lineage composition, and was
calculated based on the proportion of reads for each
IGHV family and segments normalized to the total num-
ber of reads per library (raw IGHV usage). When both
acute and post-convalescent samples were available, the
proportion of reads for each segment during the acute
(A) phase was subtracted from its corresponding value
during the post-convalescent (Pc) phase (ΔA–Pc). The
second and third approaches aimed to estimate IGHV
usage per clonotype or lineage, respectively, where the
number of clonotypes or lineages using a particular
IGHV segment was expressed as the proportion of all
clonotypes or lineages in the corresponding library using
a particular IGHV segment. Similar to the first approach,
changes of IGHV usage are expressed as the difference
of the acute phase frequency minus its corresponding
post-convalescent frequency (ΔA − Pc). Statistical evalu-
ation was done with a two-way analysis of variance
(ANOVA) with Bonferroni correction for multiple test-
ing using Graph Pad Prism v5.0. Differences were con-
sidered statistically significant if p < 0.05.
VH mutation analysis
The numbers of non-synonymous and synonymous mu-
tations were obtained with IMGT/HighVQuest [36] for
each lineage consensus. To compare the proportion of
mutations, only productive lineages were used for random
sub-sampling (1280 lineages per library, which corre-
sponded to the library with the least number of lineages).
The proportion of mutations (pM-VH), proportion of
non-synonymous mutations, and the proportion of syn-
onymous mutations were calculated as the percentage of
total mutations in the VH region, excluding the CDRH3,
divided by its length. To avoid non-independence effects
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from lineages derived from large clonotypes, SHM was
also calculated in the largest lineage per clonotype from
250 randomly sampled clonotypes. To identify differences
in the proportion of mutations per IGHV segment, the
mean global mutation proportion was subtracted from
each individual IGHV mean mutation proportion. The dif-
ference was used for unsupervised hierarchical clustering
according to IGHV segment using an uncentered correl-
ation metric for clustering with CLUSTER 3.0 [37]. We
performed multivariate comparisons among control,
DWS− A, DWS+ A, DWS− Pc, and DWS+ Pc consensus
of lineages based on different metrics including the mean
of the proportion of mutations (non-synonymous and syn-
onymous), the mean frequency of lineages, and CDRH3
length. A multilevel principal component analysis [38]
was applied in a sample of 1280 randomly chosen lineages
for each individual, and graphically visualized using biplot
graph, which is a graphical representation of principal
component 1 (PC1) versus principal component 2 (PC2),
which are selected by the proportion of explained variance
(that is, accounting for as much of the variability in the
data as possible). This analysis was conducted using R
software [39]. Non-parametric analyses (Kruskal–Wallis
test) with Dunn’s correction for multiple testing were per-
formed for comparisons among the different groups with
R software [40]. Differences were considered statistically
significant if p < 0.05.
CDRH3 convergence analysis
CDRH3 convergent signatures have been described in
acute DENV infection [41]. We used two approaches to
identify CDRH3 convergent signatures: the first was
based on searching for the previously described signatures
in our VH clonotype databases in acute infection and
post-convalescence. The second was based on de novo
identification of shared CDRH3 within our datasets. For
both approaches, the R function Find_CDR3 of Immune-
diveRsity was used [30].
Results
Donors, samples, demographic data, and sequencing
metrics
In order to characterize the impact of acute DENV in-
fection in the human B cell repertoire in terms of clin-
ical status (DWS− and DWS+) and immune status
(primary and secondary infection), we sampled periph-
eral blood from 19 patients with laboratory-confirmed
DENV infection during their febrile stage (DWS− A,
n = 10; DWS+ A, n = 9). No differences in the number
of days after onset of symptoms were found regarding
clinical (DWS− or DWS+) (Additional file 3, Table 1) or
immune status. As a reference, a second sample was ob-
tained from some individuals 6 months after the first
sample (post-convalescence) (DWS− Pc = 7, DWS+ Pc =
4) (Fig. 1a, b). Socio-demographic and clinical data are
summarized in Table 1. Of the 19 patients, only three had
a primary infection (15.8 %) during the acute stage and
the rest had secondary infections (84.2 %). All primary
cases were classified as DWS−. The predominant infecting
serotype was DENV2 (10/19; 52.6 %), followed by DENV1
(7/19; 36.8 %). We could not determine the serotype in
four patients (21.0 %) (Table 1). Sera from 15 individuals
(78.9 %) presented high titers of cross-neutralizing anti-
bodies to the four DENV serotypes, as measured by
DENV reporter particle neutralization assay [26]; one
individual showed cross-reactive titers to three DENV
serotypes; and, as expected, the three patients with
primary infections showed homotypic neutralization
(Fig. 1c, Additional file 4). Owing to the high cross-
reactivity among DENV serotypes, it was not possible to
identify which was the primary infecting serotype in sec-
ondary cases.
Table 1 Demographic data and clinical parameters
DWS− A DWS− Pc DWS+ A DWS+ Pc
Number of individuals, n 10 7 9 4
Male, n (%) 3 (30 %) 2 (28.6 %) 4 (44.4 %) 1 (25 %)
Age in years, median (range) 33 (18–50) 27 (18–50) 30 (16–47) 18 (16–46)
Days after symptom onset, median (range) 4 (1–8) 294.5 (133–323) 6 (3–9) 268 (128–309)
Type of infection, n (%) Primary 3 (30 %) 3 (42.9 %) 0 (0 %) 0 (0 %)
Secondary 7 (70 %) 4 (57.1 %) 9 (100 %) 4 (100 %)
Serotype, n (%) DENV1 2 (20 %) NA 3 (33.3 %) NA
DENV2 5 (50 %) NA 5 (55.6 %) NA
Unknown 3 (30 %) NA 1 (11.1 %) NA
Hemoglobin, mean (SD) 14.2 (1.5) UD 13.55 (2.0) UD
Platelets, mean (SD) 125.5 (78.0) UD 68.8 (34.7) UD
A acute, DWS− dengue without warning signs; DWS+ dengue with warning signs; NA not applicable, Pc post-convalescence, SD standard deviation, UD undetermined.
Percentages (%) are calculated based on n per column
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Thirty VH region IgG+ cDNA libraries of peripheral
blood B cells were generated using a generic IgHG CH1-
coding exon-specific antisense oligonucleotide for 5′
RACE-PCR amplification. A total of 2,364,822 raw and
2,044,447 pass-filter 454-Roche sequences were generated
[27]. Pass filter reads were used as the input for Immune-
diveRsity [30], which reconstructed 385,206 heavy chain
lineages derived from 146,565 heavy chain clonotypes.
The average number of lineages and clonotypes per pa-
tient was 11,553 (±6587) and 4420 (±2961), respectively
(Table 2, Additional file 5). During acute dengue infection,
there is a massive mobilization of plasmablasts to periph-
eral blood [42], and we identified a higher number IgG
lineages during acute dengue infection (Fig. 2). Rarefaction
analyses for clonotypes and entropy measurements were
consistent with a higher number of IgG B cells during
acute infection (Additional file 6). Given that the source of
the sequenced material was RNA, these results imply that
the sequenced lineages either had higher IgG expression
(i.e., plasma cells and plasmablasts) or were clonally
expanded.
Estimation of the cellular composition and origin of
sequencing reads
Results from the Monte Carlo simulation showed that
the probability of sampling an mB cell lineage larger
than 5 reads drops rapidly when the mB to ASC ratio
drops below 9:1 (Fig. 3a, Additional file 1). Because the
actual number of ASC and mB cells in our samples is
unknown, we estimated the probability of sampling an
IgG+ mB based on the previously described average IgG+
plasmablast count (56 %) during acute dengue infection
(approximately 5.6 % of CD19+ B cells). Using these pa-
rameters, the probability of sampling a single read from
an mB cell lineage was 0.015 and decreased for larger
clonotypes (Fig. 3b. Additional file 1). However, even
with a modest plasmablast increase to a proportion of
10 % (mB to ASC ratio of 9:1, or 1 % of CD19+ B cells),
A B
C
Fig. 1 Clinical specimen sampling design and DENV cross-neutralization. a Graphical representation of peripheral blood samples in relation to the
onset of symptoms. b Clinical and immune status of patients included in the study. The number of patients in each category during the acute
phase is shown. Number of post-convalescent samples is shown in parentheses. c Cross-reactivity of acute DENV infection sera to four serotypes
using the DENV reporter virus particle neutralization test. Each bar represents the number of individuals having NT50 > 1:50 to x number of
serotypes. DWS− dengue without warning signs; DWS+ dengue with warning signs
Table 2 Sequencing summary
DWS− A DWS− Pc DWS+ A DWS+ Pc
Total Media ± SD Total Media ± SD Total Media ± SD Total Media ± SD
Raw sequences 731,977 73,197 ± 25,500 460,685 65,812 ± 23,151 594,743 66,082 ± 27,433 260,066 65,016 ± 47,798
Pass filters sequences 659,621 65,962 ± 23,636 395,217 56,459 ± 22,634 499,483 55,498 ± 25,926 227,017 56,754 ± 44,401
Heavy chain clonotypes (unique) 49,616 4961 ± 2590 19,260 2751 ± 858 53,573 5952 ± 4027 10,144 2536 ± 806
Heavy chains lineages (unique) 125,631 12,563 ± 5334 60,708 8672 ± 5687 129,040 14,337 ± 8620 31,213 7803 ± 2534
A acute, DWS− dengue without warning signs; DWS+ dengue with warning signs; NA not applicable, Pc post-convalescence, SD standard deviation; media and SD
was calculated by the number of individuals in each group
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the probability of sampling an mB cell lineage larger
than 5 reads was <0.04 (Fig. 3a, Additional file 1).
This scenario changes substantially in the post-con-
valescent phase, where the predominant IgG-expressing B
cells are mB (average 95.8 %) [43, 44]. Under these condi-
tions, sampling one read derived from an mB cell is com-
mon (p = 0.64) and its probability decreases below 0.012
until a lineage size threshold of 10 reads or higher is
reached (Fig. 3c). The results of Monte Carlo simulation
indicated that in patients with acute dengue, the majority
of sequencing reads and the resulting lineages derived
from ASCs. In contrast, during post-convalescence, line-
ages above 10 reads mainly derived from ASCs. However,
we cannot exclude the possibility that in patients sampled
at early-symptom onset, the proportion of ASCs may be
similar to those sampled during the post-convalescent
phase.
Differential usage of IGHV families and segments in acute
phases
A predominant use of certain IGHV families and seg-
ments in plasmablast-derived anti-DENV antibodies has
been described [16]. Relative IGHV usage frequencies
are expected to be heavily influenced by IgG transcrip-
tion levels according to B cell functional stage. Thus, to
compare relative IGHV family and segment usage, we
analyzed IGHV family and segment usage per lineage
(Fig. 4a, b), and per clonotype (Additional file 7), as well
as IGHV family-relative and segment-relative transcrip-
tion (based on read count, regardless of clonotype or
lineage composition) (Additional file 7A, B). To identify
a potential bias in IGHV use during acute DENV infec-
tion, we measured the difference between the relative
frequencies of each IGHV family or segment during the
acute phase minus the corresponding post-convalescent
phase (ΔA − Pc). Interestingly, hierarchical clustering of
ΔA − Pc IGHV usage per lineage revealed two patient
clusters: one that showed increased IGHV3 and de-
creased IGHV1 family usage, containing all patients with
primary infections and two with DWS− with secondary
infections; and the other showing increased IGHV1 and
decreased IGHV3 family usage, containing the rest of
the patients with secondary infections including all
DWS+ patients (Fig. 4a). IGHV1 and IGHV3 usage was
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Fig. 3 Probability of sampling memory B (mB) cells and antibody-
secreting cells (ASCs) in the Rep-Seq output by Monte Carlo simulation.
The probability of sampling an mB cell of a given size (number of reads
per lineage) was calculated as described in Additional file 1. a Probability
of sampling an mB cell of a given lineage size (read number) as a
function of the proportion of mB cells in the sample (x axis). b
Simulation of a dengue infection where plasmablast mobilization
increases to 56 % of IgG+ B cells (or ~5.6 % of CD19+), with a
concomitant reduction in the relative proportion of mB cells to
44 %. c Simulation of post-convalescence where the proportion of
plasmablasts returns to basal levels (4.3 % of IgG+) and mBs dominate
the sample. In these conditions, only very large lineages (≥10 reads)
are expected to derive from ASCs













Fig. 2 Number of lineages by clinical status. Absolute number of
heavy chain lineages (ImmunediveRsity output) in acute DENV infection
and the post-convalescent period according to clinical status (one-way
ANOVA, Bonferroni correction for multiple testing). A acute,
DWS− dengue without warning signs; DWS+ dengue with
warning signs; NA not applicable, Pc post-convalescence
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different between DWS− and DWS+ (two-way ANOVA;
p < 0.01 and p < 0.001, respectively).
To identify the IGHV segments responsible for such
differences, ΔA − Pc IGHV segment usage was com-
pared. This revealed a significant increase in IGHV1-2
(two-way ANOVA, p < 0.01) and IGHV1-69 (two-way
ANOVA, p < 0.001) usage frequency in acute DWS+
(Fig. 4b, Table 3). Further analysis of differential IGHV
family or segment usage according to clonotypes consist-
ently revealed that IGHV1-69 was significantly increased
during acute DWS+ (two-way ANOVA, p < 0.001). One
additional segment belonging to the IGHV1 family,
IGHV1-18, was also significantly increased during acute
DWS− but not DWS+ (two-way ANOVA, p < 0.05)
(Table 3, Additional file 7C).
The estimation of IGHV usage has limitations because
it is based on a comparison between a predominantly
DENV-specific plasmablast repertoire (Fig. 3b) [42], with
the repertoire of a mixed IgG+ non-DENV-specific mB cell
and plasmablast population during the post-convalescent
phase (Fig. 3c). We estimated that during the post-




















































































Fig. 4 Preferential IGHV usage during acute DENV infection. a Heat map of hierarchical clustering of the difference between acute minus
post-convalescent lineage frequency (ΔA − Pc) per IGHV family. Overrepresentation of IGHV family usage during acute phase is indicated in
yellow tones, whereas blue tones indicate underrepresentation. Upper rows classify patients according to clinical status (DWS− green and
DWS+ blue) and immune status (primary orange and secondary purple) (two-way ANOVA, Bonferroni correction for multiple testing, *p < 0.05).
b Difference between acute minus post-convalescent (ΔA − Pc) according to IGHV segment, clinical status, and immune status. IGHV1-2 and
IGHV1-69 are overrepresented in acute DWS+ (columns, DWS− green and DWS+ blue) and immune status (primary orange and secondary purple).
A higher frequency of lineages using IGHV1-18 and IGHV1-69 in DWS+ is shown in red tones. DWS− dengue without warning signs; DWS+ dengue
with warning signs; NA not applicable
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containing 30 reads or higher was very low (≤2.06447E− 06).
To compare IGHV usage in plasmablasts during the acute
and post-convalescent phases, we filtered out lineages
below 30 reads, yielding similar results to those in the bulk
analysis, but adding IGHV2-5 as significantly overrepre-
sented (ANOVA p < 0.001) during the acute phase. Table 3
summarizes the analysis of differential IGHV family/seg-
ment usage in terms of the level of aggregation (lineages,
clonotypes, relative expression, and filtering according to
lineage size) and of differences between clinical and im-
mune status. Because this analysis was performed using
unsorted B cell populations, it is not possible to know the
exact number of B cells involved. However, these results
suggest a potential selection bias by DENV of B cells using
segments of the IGHV1 family, particularly IGHV1-2,
IGHV1-18, and IGHV1-69. Although IGHV1-2 raw ex-
pression was significantly increased in acute DWS+ (Add-
itional file 7B; two-way ANOVA, p < 0.05), no differences
were found at the clonotypic frequency level (Additional
file 7C). Such differences in relative IGHV transcription
(raw IGHV usage) may imply different proportions of cells
with high IgG versus low IgG transcription, and not differ-
ences in the number of B cells using a particular IGHV
segment. Biased usage of particular IGHV segments in re-
sponse to a common pathogen in different individuals
suggests that recognition is highly influenced by VH re-
gions other than CDRH3 [45]. Thus, the composition of
such biased IGHV expansions should be polyclonal. In-
deed, digital CDRH3 “spectra-typing” for biased IGHV
segments at the lineage level confirmed this to be the case
(Additional file 8).
To address if allelic variation in IGHV segment could
influence the expansion of particular IGHV segments,
we characterized the IGHV genotypes for IGHV1-2,
IGHV1-18, and IGHV1-69 (Additional file 9). We found
no correlation between allele type and expansion in the
corresponding IGHV segments.
Lower SHM in the acute phase
A hallmark of the adaptive humoral immune response is
affinity maturation as a result of antigen re-exposure.
Affinity maturation occurs by SHM and mainly affects
antigen-selected GC B cells [12]. SHM is mechanistically
coupled with CSR [46]. Given that the majority of the
samples analyzed in this study focused on the IgG com-
partment from secondary infections (class switched B
cells), higher levels of SHM in B cells would be expected.
In order to detect whether higher levels of SHM had in-
deed occurred, the percentage of mutations in the IGHV,
using the germ-line as reference segments, was calcu-
lated for each consensus of lineages [36]. We ob-
served that acute DENV infection had an overall
lower proportion of SHM than the corresponding
level during post-convalescence, regardless of the clin-
ical (Fig. 5a) or immune status (Fig. 5b). This effect
was different from that observed in the 2008–2009
trivalent inactivated influenza vaccine (TIV), in which
the proportion of SHM at 7 days post-vaccination in-
creased (Fig. 5a) [23]. Interestingly, SHM levels were
significantly lower in DWS+ than in DWS−, and in
secondary than in primary DENV infection (Fig. 5b).
Moreover, among acute secondary cases, lower SHM
levels were found in DWS+ than in DWS− (Fig. 5a).
SHM is the basis for selection of high-affinity antibodies
[12]; nevertheless, calculation of non-synonymous muta-
tions yielded the same results as overall mutation rates
(Additional file 10).
In mice, marginal zone (MZ) B cell subsets are less
dependent on T cell help, can be class-switched to IgG,
have lower SHM rates, and have a differential IGHV
usage [47], suggesting that in human DENV infection,
the participation of a particular IgG+ B cell subset using
unmutated or poorly mutated IGHV segments may take
place. To determine if the reduction of SHM particularly
affected certain IGHV segments during acute DENV in-
fection, we calculated SHM rates according to IGHV
segment. Significantly lower levels of SHM during acute
DENV infection compared to post-convalescence were ob-
served for IGHV1-2, IGHV1-18, and IGHV1-69 (p < 0.001)
(Additional file 11). As for the total repertoire, significantly
lower levels of SHM of IGHV1-2 were observed in acute
DWS+ compared to acute DWS− (p < 0.001) and in acute




Relative transcription Clonotypes frequency Lineages frequency
Clinical status Immune status Clinical status Immune status Clinical status Immune status
IGHV1 * (NS) * (NS) ** (NS) NS (NS) ** (NS) NS (NS)
IGHV3 * (NS) * (NS) *** (NS) NS (NS) *** (NS) * (NS)
IGHV1-2 * (*) NS (*) NS (**) NS (NS) ** (**) NS (NS)
IGHV1-18 NS (NS) NS (NS) * (*) NS (NS) NS (NS) NS (NS)
IGHV1-69 *** (NS) NS (NS) *** (**) * (NS) *** (NS) NS (NS)
IGHV2-5 NS (NS) NS (NS) NS (***) NS (NS) NS (*) NS (NS)
*p < 0.05; **p < 0.01; ***p < 0.001; NS not significant. Two-way ANOVA with Bonferroni correction. Values in parentheses derive from filtering out lineages with ≥
than 30 reads
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secondary versus acute primary infections (Additional
file 11A, B). In the case of IGHV1-18 and IGHV1-69, acute
secondary infection had significantly lower SHM levels
than acute primary infection (Additional file 11D–F); how-
ever, no significant differences were observed between
acute DWS+ and DWS− (Additional file 11).
Regarding IGHV overrepresentation analysis, to avoid
comparing SHM levels in a mainly DENV-specific plas-
mablast repertoire during the acute phase with a mixed
non-DENV-specific plasmablast and non-DENV-specific
mB cell repertoire during the post-convalescent phase,
we filtered out all lineages with fewer than 30 reads
(Additional file 1). Thus, we compared the proportion of
SHM in DENV-specific plasmablasts during the acute
disease with non-DENV-specific plasmablasts during the
post-convalescent phase. The SHM levels were signifi-
cantly lower during the acute phase, although there was
no significant difference in IGHV1-2 SHM levels in
DWS− patients (Fig. 6).
To avoid potential non-independence effects imposed
by sampling clonally related lineages, we also performed
the same SHM estimation but instead of random lineage
subsampling in each library, we randomly subsampled
250 clonotypes and performed the SHM analysis in the
corresponding largest lineage. The results using this ap-
proach agreed with the lower SHM rates in the bulk
analysis, indicating that our SHM estimates were not the
result of sampling bias (Additional file 12).
Moreover, to discard the possibility that clonotype
(CDRH3) clustering threshold identity (97 %) could arti-
ficially sub-estimate SHM levels, we performed an ana-
lysis with the reconstructed repertoire at a CDRH3
threshold identity of 92 %. Under these parameters,
SHM levels were equally low during the acute phase
(Additional file 13).
As shown in Figs 5 and 6a, global SHM rates were
lower in acute DENV infection, suggesting that this ef-
fect is not restricted to only IGHV1-2, IGHV1-18, and
IGHV1-69. Calculation of SHM rates for all IGHV
segments during acute and post-convalescent DENV in-
fection and for controls (subjected to hierarchical cluster-
ing according to IGHV segment) revealed significantly
higher SHM rates in controls and post-convalescent indi-
viduals than in patients with acute DENV infection
(Mann–Whitney U test, p < 0.001) (Additional file 14).
Because the number of lineages belonging to a given B
cell clonotype is the result of SHM, a straightforward
prediction derived from lower SHM rates is that the
number of lineages per heavy chain clonotype during the
acute phase of DENV infection will also be low. Consist-
ent with our observations, the clonotype per lineage ratio
(1/lineages) was significantly reduced during the acute
phase of DENV infection in both DWS+ and DWS−
(Kruskal–Wallis test, Dunn’s correction, p < 0.001).
Finally, we performed a multivariate analysis based on
multilevel principal component analysis to search for as-
sociation patterns between SHM rates, clonal selection
(lineage relative frequency), and clinical condition. We
used the mean proportion (%) of all mutations, non-
synonymous and synonymous mutations in the IGHV
segment, as well as the mean relative frequency of 1280
randomly chosen lineages as variables for the analysis.
CDRH3 length was excluded because it did not contrib-
ute significantly to variance. Two components, PC1 and
PC2 explained 76.3 % and 22.6 % of the variance, re-
spectively, with a cumulative proportion of 98.9 %. Mean





































Fig. 5 IgG B cell repertoire during acute DENV infection is associated with low somatic hypermutation (SHM) rates. SHM rates are shown
according to clinical status (a) and according to immune status (b), measured as the proportion of mutations along the VH region [pM-VH (%)].
a The global SHM rate during the acute phase is significantly lower in acute DENV infection, but not as a result of the 2008–2009 seasonal
trivalent inactivated influenza vaccination (TVI). b Global SHM rates are lower in the acute phase of DENV infection and significantly lower in
acute secondary infection than in acute primary infection. Dengue without warning signs (DWS−) acute (A), green; DWS− post-convalescence (Pc),
dark green; dengue with warning signs (DWS+) A, blue; DWS+ Pc, dark blue; d0 TVI, pink; d7 TVI, red; primary infection A, orange; primary infection
Pc, brown; secondary infection A, light purple; secondary infection Pc, dark purple (Kruskal–Wallis test, Dunn’s correction for multiple testing,
**p < 0.01, ***p < 0.001)
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PC1 score was significantly different between acute
DWS+ and post-convalescence (p < 0.01) (Fig. 7a). Al-
though PC1 was lower in acute DWS− than in post-
convalescence, no significant differences were found.
However, PC1 was significantly lower in DWS− and
DWS+ than in the healthy control group (p < 0.05 and
p < 0.01, respectively). Bi-plots of PC1 and PC2 showed
four major clusters, one containing the majority of the
healthy control samples, a second containing DWS+, a
third containing most of the DWS− sample, and a
fourth containing most of the post-convalescent pa-
tients, regardless of clinical status during acute disease
(Fig. 7b). Taken together, mutation analysis using su-
pervised and non-supervised approaches robustly sup-
ports that circulating IgG+ B cells during acute DENV
infection were less hypermutated than IgG+ B cells in
the post-convalescent phase or in healthy controls.
Convergent CDRH3 signatures in acute dengue infection
Convergent antibody signatures in different individuals
responding to a variety of viral infections (reviewed in
[48]), including dengue virus infection, have been
described [41]. We used as a query a dataset of 151
convergent CDRH3s [41] to search for near-identical
matches (one mismatch tolerance) or identical matches
on our acute or post-convalescent databases. We found
1098 shared CDRH3 in at least three individuals during
acute infection (19 cases) versus 53 shared CDRH3 in
at least three post-convalescent individuals (10 cases).
Correcting for differences in the total number of clo-
notypes, 3.6 % of clonotypes were shared in at least
three individuals during acute infection compared to
0.44 % during post-convalescence (8.3-fold difference)
(Fig. 8a). A similar approach searching for identical
CDRH3s revealed that 0.23 % of clonotypes (68) were
shared in at least three individuals during acute infec-
tion compared to 0.03 % (3) during post-convalescence
(9.1-fold difference) (Fig. 8a). Only three convergent
CDRH3s were found in no more than two individuals
of a group of healthy individuals prior to vaccination
with TIV (Fig. 5a).
We also searched for convergent CDRH3s regardless
of their presence in the dataset described in [41] (de
novo). We found 1365 clonotypes representing 269






































































Fig. 6 Low somatic hypermutation (SHM) rates in IgG antibody-secreting cells (ASCs) during acute DENV infection compared to steady state ASCs
in post-convalescence (Pc). As a result of Monte Carlo simulation, we estimated that it was very unlikely for samples to have a memory B (mB)
lineage larger than 30 reads during post-convalescence (p = 2.0645E − 06). The SHM rates were recalculated in in silico-sorted ASCs during
post-convalescence, and classified according to clinical status. a Global SHM levels. b SHM in lineages using IGHV1-2. c SHM in lineages using
IGHV1-18. d SHM in lineages using IGHV1-69. A acute, DWS− dengue without warning signs, DWS+ dengue with warning signs
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identical CDRH3s shared in at least three individuals
during acute infection (0.9 % of all clonotypes in acute
infection). Interestingly, among shared clonotypes there
was a predominant CDRH3 length of 10 residues
(70 %) (Fig. 8b–e). Two CDRH3s, ARQFGNWFDS and
ARQWGNWFDL, were shared in 10 individuals (10/19,
52 % of individuals) (Fig. 8e). A CDRH3, ARQLGNWFDS,
present in nine individuals was similar, although not iden-
tical to, the ARQIGNWFDP signature described in [41]
(differences in italics). Finally, we addressed whether the
convergent heavy chain clonotypes were less hypermu-
tated. We sampled the largest lineage of convergent and
non-convergent VH clonotypes as in Additional file 12.
As expected, lower SHM rates were found in convergent
VH lineages (Fig. 8f).
Discussion
Understanding of the immune response to DENV infec-
tion has been hampered by the lack of adequate experi-
mental models [49], but represents an urgent goal for
developing safe vaccination strategies and as the basis
for understanding the role of population immunity in
disease transmission dynamics [50]. Using an IgG Rep-
Seq approach, we have shown that in the course of an
acute DENV infection there is an increase in B cell
clonal diversity in peripheral blood, presumably as a re-
sult of DENV-specific plasmablast mobilization. We also
documented differences in the relative frequencies of B
cells using certain IGHV segments belonging to the
IGHV1 family according to clinical status. More import-
antly, we found a paradoxically low SHM frequency in
the acute phase, as compared to the corresponding post-
convalescent phase. Also paradoxical is the fact that the
SHM frequency was even lower in secondary than in
primary DENV infections. Interestingly, for some IGHV
segments such as IGHV1-2, the SHM rates were lower
in DWS+ compared to DWS− infection.
HTS of the B cell repertoire has been applied to ex-
plore higher order structural properties of the antibody
repertoire [35, 51], track leukemia residual disease [52],
uncover clonal lineages and patterns of SHM profiles in
broadly neutralizing antibodies in human immunodefi-
ciency virus [53], as well as to analyze the antibody re-
sponse in influenza virus infection [54] and vaccination
[23, 55, 56]. It is particularly relevant for the work pre-
sented here to explore convergent antibody signatures in
DENV infection [41]. Being a relatively recently devel-
oped approach, there are substantial methodological and
analytical differences by which the research groups have
coped with the challenge of mining the lymphocyte rep-
ertoire complexity. An important methodological differ-
ence is whether the starting material for Ig sequencing is
DNA or RNA. Sequencing DNA has the advantage of
providing a single copy per B cell as template for PCR
amplification, thus, assuming unbiased PCR amplifica-
tion, the clonal size is a reflection of the number of clon-
ally related B cells in a given clone. An important
advantage of using RNA-derived libraries for sequencing,
particularly those generated by 5′RACE-PCR, is that less
PCR amplification bias is expected owing to the use of a
single primer pair based on invariant amplicon flanks
[20]. However, in contrast to DNA sequencing, differ-
ences in B-cell receptor (BCR) expression related to dif-
ferentiation stage hamper an accurate estimation of
clonal composition and size. To cope with potential dis-
tortions of Ig expression levels derived from unsorted B
cells, we collapsed sequencing reads according to com-
mon clonal origin (heavy chain clonotypes) or further into
lineages (consensus of sequences from a common clonal
origin displaying a differential SHM pattern). Using this





































Fig. 7 Multilevel principal component analysis of mutational parameters in acute DENV infection. a Single principal component plot of PC1,
which represents the number of total, non-synonymous, and synonymous mutations in IGHV segments of controls (red), acute DWS− (DWS− A,
green), post-convalescent DWS− (DWS− Pc, dark green), acute DWS+ (DWS+ A, blue), and post-convalescent DWS+ (DWS+ Pc, dark blue). Lower
scores for PC1 were observed during the acute phase of DENV infection. DWS− A and DWS− Pc were significantly different (Kruskal–Wallis test,
**p < 0.01). b Bi-plot showing clustering of patient samples according to clinical status. DWS− dengue without warning signs; DWS+ dengue with
warning signs
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Fig. 8 Complementarity determining region heavy 3 (CDRH3) signatures in acute DENV infection. A search for convergent CDRH3 signatures was
performed using previously published data [41] or de novo, using the Find_CDR3 function of ImmunediveRsity [30]. a Proportion of identical or
similar (one-mismatch) CDRH3s in our acute and post-convalescent datasets compared to a set of 151 convergent CDRH3s associated with acute
DENV infection previously described [41]. b CDRH3 length distribution of de novo identified convergent CDRH3 signatures compared to overall
CDRH3 length distribution. We found 1365 clonotypes representing 269 identical CDRH3 shared in at least three individuals with acute DENV
infection. A predominant 10-residue CDRH3 signature was found. c Amino acid residue composition in 10-residue-long CDRH3 (left) and in
10-residue-long de novo identified convergent CDRH3s associated with DENV infection (right). d LOGO plot of consensus 10-residue-long
convergent CDRH3 signatures. e Absolute number of shared CDRH3s as a function of the number of individuals who share them. f Proportion
of somatic hypermutation per lineage in convergent and non-convergent CDRH3s in acute DWS – (green) and DWS+ (blue). DWS − dengue
without warning signs; DWS + dengue with warning signs
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approach, IGHV frequency usage and SHM levels were
quantified with respect to the corresponding denominator,
reducing biases related to Ig expression levels.
In the context of DENV infection, we used the absolute
lineage number, rarefaction analysis, and Shannon–Weaver
index (entropy) as an approximation to estimate diversity
in a subsample B cell repertoire (Fig. 2, Additional file 6).
These analyses suggest that during acute DENV infection
there is an increase in B cell diversity. An increase in B cell
clonality due to clonal expansion using P[collision] was re-
cently described [41]. We argue that our results are not
contradictory to this; P[collision] is estimated by replicate
sampling and measures the probability of finding clonally
related B cells in the replicates. Thus, clonal expansions
can be readily assessed and proved during the acute phase
of DENV infection [41]. Here, because we used RNA as
the starting material and sequenced a unique sample,
we cannot evaluate clonal expansion directly (because
clonally related sequences may be clustered during the
reconstruction of clonotypes and lineages). Neverthe-
less, we interpret the higher species richness in rarefac-
tion analysis and the increased Shannon–Weaver index
as the result of higher numbers of circulating B cells,
which could be explained, at least partially, by the
massive plasmablast migration that occurs during the
acute phase of the disease [15, 19, 42, 57].
Preferential IGHV usage has been described in
antigen-specific B cells in models of cytopathic viral in-
fection. In vesicular stomatitis virus (VSV) infection in
mice, a rapid initial IgG-neutralizing response of defined
germline unmutated IGHV segments (VHQ52) confer
protection. Secondary challenge is associated with a shift
in the use of other segments (VH7183 and VHJ558) and
the occurrence of SHM [58, 59].
The generation of unmutated IgG+-switched mB cells
beyond the VSV model has been described in a model of
Polyomavirus infection [60] in Bcl6-deficient mice,
which are devoid of TFH cells and thus lack a GC reac-
tion [61, 62]. Also in mice, an extrafollicular response to
Salmonella with sufficiently low levels of SHM to pro-
mote affinity maturation was recently described [63].
Strikingly similar results have been obtained in human
Rotavirus infection, where the response to VP6 is medi-
ated in part by class-switched mB cells exhibiting low
hypermutation rates that predominantly use IGHV1-46
[64]. These observations have been generalized as part
of the concept of “natural antibodies,” which can be
IgM, IgG, and IgA. These are encoded by unmutated
germline antibody genes, are produced as a rapid T cell-
independent response against a variety of viruses with
relatively high affinity, and recognize repetitive structures
such as viral capsids, but are intrinsically poly-reactive
[65]. A notable example of this type are IGHV1-69-coded
antibodies that have been recurrently implicated in
recognition against influenza A, hepatitis C, and human
immunodeficiency viruses [45, 48, 66–70].
In accordance with a natural antibody response,
DENV activates poly-reactive, natural IgG B cells after
primary and secondary infection [15]. Studies with hu-
man anti-DENV monoclonal antibodies have revealed
that a large proportion of DENV-reactive human anti-
bodies are highly cross-reactive [17, 18] and recognize
quaternary epitopes present only on the viral particle,
but not in monomeric E protein [71]. Here we found
low levels of SHM and differential usage of IGHV1-2,
IGHV1-18, and IGHV1-69 in acute DWS− and DWS+,
suggesting their potential implication in natural DENV
recognition, cross-reactivity, and antibody-dependent
enhancement. The 5′RACE-PCR approach used for VH
library generation rules out a possible bias for amplifica-
tion of unmutated over hypermutated sequences. We
propose that during acute primary and secondary DENV
infections, at least two effector B cell differentiation
pathways co-occur, one consisting of a natural poorly
mutated antibody IgG response (similar to that occur-
ring in the VSV infection model and Polyomavirus infec-
tions in mice and Rotavirus infections in humans), and
the other of a classic secondary T cell- and GC-
dependent B cell response pathway (Fig. 9). Although
the relative contribution of both pathways to SHM levels
in peripheral IgG+ B cells is difficult to assess, the pre-
sented evidence suggests that the GC-i response is
strong enough to significantly influence the levels of
SHM.
Interestingly, lower IgG SHM rates were found in
acute disease, and appeared to be more accentuated in
DWS+ than in DWS−, and in secondary more than in
primary acute infections. This effect was particularly
clear in IGHV1-2-expressing IgG B cells. Consistent with
its role in natural antibody recognition, IGHV1-2 is fre-
quently used by neonatal cord blood IgM+ lymphocytes
[72] and in MZ B cell lymphomas [73, 74], which are
thought to derive from chronic pathogen-mediated se-
lection [75]. MZ B cells are capable of mounting class-
switched and class-unswitched T-independent as well as
T-dependent B cell responses [47]. Normal MZ B cells
produce rapid responses to blood-borne pathogens and
could be the source of natural IgM and IgG responses
against DENV. However, no modification in MZ B cells
was observed in children with acute DENV infection
[19]. Moreover, human MZ B cells are usually hypermu-
tated [47], thus suggesting that during acute DENV in-
fection, MZ B cells are not the source of circulating
poorly mutated IgG+ B cells.
Among other limitations of the HTS approach is that
our VH libraries derived from total peripheral blood
IgG-expressing B cells; as such, we have no information
regarding the relative contribution of different B cell
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subsets or their antigen specificity. However, in support
of our results, a preferential use of the IGHV1 family in
plasmablasts, but not mB cells, has been described in
acute DENV infection [16]. Moreover, the high propor-
tion of DENV-specific plasmablasts occurring during
acute infection [42] provides further support to the
claim that the observed repertoire differences may be
DENV-specific as well.
Another limitation of working with unsorted IgG+ B
cells, namely mB cells and ASCs (plasmablasts and
plasma cells) is that their relative proportions vary dra-
matically during acute dengue infection, making it diffi-
cult to compare their respective repertoires. We used a
Monte Carlo simulation method to estimate the prob-
ability of sampling either subpopulation depending on
the relative proportions of mB cells and ASCs. A limita-
tion of this simulation is that it cannot discriminate ASC
from mB cells that have proliferated extensively. How-
ever, the lack of variation in the proportion of mB cells
in acute dengue argues against this possibility [19, 57].
Interestingly, we estimated that the probability of sam-
pling mB cells during acute dengue is negligible owing
to the large number of plasmablasts and their corre-
sponding high Ig expression levels. Likewise, during the
post-convalescence phase, the probability of sampling an
mB cell larger than 30 reads is negligible as well. This
approach allowed us to partition the repertoire accord-
ing to Ig expression level and to confirm our observa-
tions regarding IGHV usage and SHM level differences
during acute disease. These experiments also highlight
an additional advantage of using 5′RACE-PCR for
Rep-Seq.
We are beginning to elucidate the molecular basis for
T-independent CSR to IgG. In mice, TLR7 and TLR9
synergize with BCR signaling to promote activation-
induced cytidine deaminase expression, which is re-
quired for CSR and SHM [76]. Although both processes
are functionally coupled, it is not clear how SHM is
prevented in B cells undergoing T-independent CSR.
TLR-mediated signaling pathways are implicated in
promoting T-independent CSR [76] and T-independent
IgG responses against Polyomavirus require MyD88 [77].
Endosomal DENV recognition by TLR7 could provide a
synergic signal with the BCR for T-independent CSR anti-
DENV cross-reactive B cells (Fig. 9).
The proposed model of extra-follicular B cell re-
sponses offers a potential explanation for the production
of low-affinity sub-neutralizing and cross-reactive IgG
Fig. 9 Proposed model for B cell responses in secondary lymphoid organs during DENV infection. DENV recognition by naïve B cells and during
early primary infection occurs in extra-follicular regions and induces a rapid differentiation to Ig-switched antibody-secreting cells (ASCs) secreting
unmutated poly/cross-reactive IgG. This pathway may be initiated by DENV low-affinity interactions with B cells using an “innate” IGHV
segment such as IGHV1-69 [70] that promotes receptor-mediated endocytosis and TLR7 recognition. Both signals promote T-independent activation
and class switch recombination (CSR). Later, the classical germinal center T-dependent response develops, peaking 1–2 weeks after symptoms onset. A
secondary infection with a different serotype triggers the same “natural” B cell response derived from naïve B cells that temporally overlaps with a
more rapid secondary T-dependent B cell response
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antibodies that may promote disease enhancement.
Thus, in the case of DENV vaccination and analogously
to observations in Polyomavirus-immunized mice [60],
strategies that promote T-independent B cell responses
(i.e., TLR7 agonist) could be associated with a higher risk
of severe disease upon reinfection than strategies that do
not [78, 79].
Conclusions
Our results in B cell repertoire mining suggest that dur-
ing acute dengue infection, in parallel with a GC-
dependent pathway, a GC-independent effector differen-
tiation pathway may occur, which manifests as preferen-
tial IGHV gene use and low SHM in IgG class-switched
B cells. This non-GC pathway may not be restricted to
primary infections, given that SHM levels were even
lower in secondary acute infections and was more strik-
ing in acute DWS+. Further research is required to
obtain definitive proof of a GC-independent B cell differ-
entiation in response to dengue infection, as well as to
define the role of poorly mutated IgG in terms of poly-
reactivity and ADE. Nevertheless, our findings are rele-
vant for understanding of the immune response to
DENV and future vaccine development.
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simulation model was built, including the sources of information regarding
relative amounts of the relevant subpopulations (IgG+ mB cells and ASCs),
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Additional file 2: Clonotype and lineage clustering by
ImmunediveRsity. Raw IgG HTS data was subjected to repertoire
reconstruction and analysis using ImmunediveRsity. Briefly, ImmunediveRsity
assigns IGHV gene to each sequence and clusters them according to IGH
clonotypes, which are composed of reads with the same IGHV-IGHJ
rearrangement and quasi-identical CDRH3 (≥97 % identity at the nucleotide
level). Within a clonotype, one or more lineages can be defined based on
SHM pattern (99.5 % identity). IGHV usage frequency can thus be expressed
as the proportion of reads using a particular IGHV segment (relative
transcription), regardless of clonotype origin, or can be expressed as the
proportion of IGH clonotypes or lineages using a particular IGHV segment
regarding the total amount of clonotypes or lineages, respectively.
(PDF 35 kb)
Additional file 3: Days after onset of clinical illness for blood
sampling according to clinical status. DWS- A, green; DWS− Pc, dark
green; DWS+ A, blue; DWS+ Pc, dark blue. (One-way ANOVA, p > 0.05, not
significant). (PDF 16 kb)
Additional file 4: Neutralization summary of DENV RVPs by human
sera. The 50 % neutralization titers (NT50) are shown as reciprocal serum
dilutions. (XLS 29 kb)
Additional file 5: Reads, clonal groups, and lineages numbers per
individual and condition. The table shows the number of raw and used
sequences as well as the number of clonotypes and lineages per
individual. (XLS 30 kb)
Additional file 6: Higher clonal diversity during acute phase than in
the post-convalescent phase, regardless of clinical classification.
Rarefaction analysis of acute vs. post-convalescent samples according to
clinical status, (A) DWS− (A, green and Pc, dark green) and (B) DWS+ (A,
blue and Pc, dark blue); and immune status, (C) primary (A, orange and Pc,
brown) and (D) secondary infection (A, light purple and Pc, dark purple)
(two-way ANOVA with Bonferroni correction, *p < 0.05; **p < 0.01). Shannon–
Weaver entropy values for heavy chain clonotypes according to (E) clinical
status and (F) immune status and for heavy chains lineages according to (G)
clinical status and (H) immune status. (DWS− A, green; DWS− Pc, dark green;
DWS+ A, blue; DWS+ Pc, dark blue; primary infection acute, orange; primary
infection Pc, brown; secondary infection acute, light purple; secondary
infection Pc, dark purple) (For E–H, one-way ANOVA with Bonferroni
correction, *p < 0.05; **p < 0.01). (PDF 78 kb)
Additional file 7: Preferential IGHV transcription and usage during
acute DENV infection. (A). Heat map of hierarchical clustering of the
difference between acute minus post-convalescent read relative frequency
(ΔA − Pc) per IGHV family. Over-transcription of IGHV family during acute
phase is indicated in yellow tones, whereas blue tones indicate under-
transcription. Upper rows classify patients according to clinical status
(DWS−, green and DWS+, blue) and immune status (primary, orange and
secondary, purple) (two-way ANOVA, Bonferroni correction for multiple
testing, *p < 0.05). (B) Relative transcription difference between acute
minus post-convalescent (ΔA − Pc) according to IGHV segment and
clinical status. IGHV1-2 and IGHV1-69 are overexpressed in acute DWS+
(two-way ANOVA, Bonferroni correction for multiple testing, *p < 0.05).
(C) Difference between the relative IGHV segment use per clonotypes
(rows) in acute minus post-convalescent (ΔA − Pc) according to clinical
status (columns: DWS−, green and DWS+, blue) and immune status
(primary, orange and secondary, purple). Higher frequency of clonotypes
using IGHV1-18 and IGHV1-69 in DWS+ is shown in red tones (two-way
ANOVA, Bonferroni correction for multiple testing, *p < 0.05). (PDF 131 kb)
Additional file 8: Digital CDRH3 “spectratyping” of acute phase
DENV infection. CDRH3 “spectratyping” of all segments and according
to IGHV1-2, IGHV1-18, and IGHV1-69 segments based on the CDRH3 size
of 1280 lineage subsample. Clinical and immune status is shown in upper
bars. CDRH3 length (bp) is shown in x axis and lineage relative frequency
is shown in y axis (color bars: DWS−, green and DWS+, blue. Upper lines:
DWS−, green; DWS+, blue; primary, orange; secondary, purple). (PDF 619 kb)
Additional file 9: IGHV allelic variation in patients with DENV
infection. ImmunediveRsity output data in raw reads were used for allele
calling. The matrix depicts each individual and the presence (dark blue) of
absence (gray) of IGHV1-2, IGHV1-18, IGHV1-69, and IGHV2-5 alleles.
(PDF 22 kb)
Additional file 10: Absolute number of non-synonymous mutations.
Quantitative analysis of non-synonymous somatic hypermutation
(DWS− A, green; DWS− Pc, dark green; DWS+ A, blue; DWS+ Pc, dark blue)
(Kruskal–Wallis test for non-parametric data with Dunn’s multiple
comparison test, *** p < 0.001). (PDF 1967 kb)
Additional file 11: Somatic hypermutation rates in selected IGHV
segments according to clinical and immune status. SHM rates are
shown according to clinical status (A, C, and E) and according to immune
status (B, D, and F) measured as the proportion of mutations along the
VH region [pM-VH (%)]. (A) SHM rates of IGHV1-2 regarding clinical status
and (B) immune status. (C) SHM rates of IGHV1-18 regarding clinical
status and (D) immune status. (E) SHM rates of IGHV1-69 regarding
clinical status and (F) immune status. (DWS− A, green; DWS− Pc, dark
green; DWS+ A, blue; DWS+ Pc, dark blue; primary infection acute, orange;
primary infection Pc, brown; secondary infection acute, light purple;
secondary infection Pc, dark purple) (Kruskal–Wallis test, Dunn’s correction
for multiple testing, **p < 0.01, ***p < 0.001). (PDF 886 kb)
Additional file 12: SHM rates in global and selected IGHV segments
of randomly subsampled clonotypes. Each dot represents the
percentage of mutations in the largest lineage of 250 randomly sampled
clonotypes per individual, classified according to clinical status. (A) Global
mutation rates; (B) IGHV1-2; (C) IGHV1-18; and (D) IGHV1-69 (DWS− A, green;
DWS− Pc, dark green; DWS+ A, blue; DWS+ Pc, dark blue) (Kruskal–Wallis test,
Dunn’s correction for multiple testing, **p < 0.01, ***p < 0.001). (PDF 483 kb)
Additional file 13: SHM rates in global and selected IGHV segments
in the ImmunediveRsity-reconstructed repertoire using a CDRH3
identity clustering threshold of 92 %. Each dot represents the
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percentage of mutations in randomly sampled lineages per individual,
classified according to clinical status. (A) Global mutation rates; (B) IGHV1-2;
(C) IGHV1-18; and (D) IGHV1-69 (DWS− A, green; DWS− Pc, dark green;
DWS+ A, blue; DWS+ Pc, dark blue) (Kruskal–Wallis test, Dunn’s correction for
multiple testing, **p < 0.01, ***p < 0.001). (PDF 2177 kb)
Additional file 14: Heat map representation of SHM according to
IGHV segment (rows) and clinical status (columns). Acute DENV
infection had significantly lower levels of SHM than post-convalescent
and control samples (Mann–Whitney U test for non-parametric data,
*** p < 0.001). (PDF 43 kb)
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